Corporate Finance

The precious metals miner appoints a new Chair and achieves 50% female board representation, signaling a strategic pivot to deepen its Moroccan growth.

EXL's new Gold Tier status with Databricks isn't just a partnership upgrade; it's a strategic move to solve AI's biggest business problem: data governance.

A landmark deal for CEL-SCI’s cancer drug Multikine in Saudi Arabia isn't just about a new market; it’s a case study in national ambition and biotech finance.

Momentus just secured another $25M, its second major cash infusion in weeks. Is this a desperate lifeline or a strategic launchpad for orbital dominance?

The Chinese insurtech's massive share consolidation is a desperate bid to stay on Nasdaq, but it reveals deeper struggles facing Chinese ADRs in the US.

As Madonna and Absolut partner for 'Confessions II,' we unpack the financial and cultural mechanics of a deal built on shared history and experiential marketing.

By upgrading to the OTCQX market, junior explorer Tesoro Gold isn't just changing its ticker; it's tapping a vital financial system to fund a massive Chilean gold project.

As Xtract One woos investors in Vegas, its AI security tech promises safety without sacrificing freedom. But can it scale its vision of a frictionless world?

A new partnership between a drone AI firm and a rail engineer promises to bring predictive maintenance and digital twins to India's vast, aging railway network.

With its new Series A, Aton Health isn't just growing; it's validating a model where research is seamlessly integrated into routine patient care.

A major shift is underway as crypto-native capital floods into traditional assets, from SpaceX pre-IPO tokens to US equity futures, signaling a new era of financial infrastructure.

As market volatility surges, traders face new risks and opportunities. A deep dive into the strategies and platform tech defining success in today's high-stakes environment.

A new survey shows Asians value independence over inheritance, yet a massive gap between intention and action threatens to derail their plans for self-reliance.

With a $20M Series A led by L Catterton, Dr. Muneeb Shah's REMEDY is disrupting skincare. Here's how accessible science is winning over consumers.

AM Best's recent 'Excellent' rating for Weston2038's notes is more than a headline. It's a vote of confidence in a hidden world of financial architecture.

Eos is asking shareholders to fund a pivotal venture for US energy storage. But is the promise of long-term growth worth the immediate cost of dilution?

Beyond a simple payout, BrightView's tenth consecutive cash dividend reveals a disciplined strategy fueling stability and innovation in commercial landscaping.

With a record-breaking IPO and over $1.2 billion raised this year, Parabilis Medicines is attacking diseases once thought untouchable. But can its Helicon platform deliver?

AM Best's 'a-' rating on Ameriprise's new notes isn't just a grade; it's a testament to strategic foresight and a beacon for investors.

As economic jitters push investors toward tangible assets, a new ranking names the top Gold IRA firms. But is this modern gold rush a savvy move or a costly trap?